JP2016500698A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016500698A5 JP2016500698A5 JP2015539750A JP2015539750A JP2016500698A5 JP 2016500698 A5 JP2016500698 A5 JP 2016500698A5 JP 2015539750 A JP2015539750 A JP 2015539750A JP 2015539750 A JP2015539750 A JP 2015539750A JP 2016500698 A5 JP2016500698 A5 JP 2016500698A5
- Authority
- JP
- Japan
- Prior art keywords
- gdf11
- activity
- level
- seq
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261718126P | 2012-10-24 | 2012-10-24 | |
| US61/718,126 | 2012-10-24 | ||
| PCT/US2013/066350 WO2014066486A2 (en) | 2012-10-24 | 2013-10-23 | Biomarker for use in treating anemia |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131226A Division JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016500698A JP2016500698A (ja) | 2016-01-14 |
| JP2016500698A5 true JP2016500698A5 (enExample) | 2016-12-08 |
| JP6401171B2 JP6401171B2 (ja) | 2018-10-03 |
Family
ID=50545462
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015539750A Active JP6401171B2 (ja) | 2012-10-24 | 2013-10-23 | 貧血の治療に使用するためのバイオマーカー |
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018131226A Pending JP2018184428A (ja) | 2012-10-24 | 2018-07-11 | 貧血の治療に使用するためのバイオマーカー |
| JP2020108569A Active JP7146850B2 (ja) | 2012-10-24 | 2020-06-24 | 貧血の治療に使用するためのバイオマーカー |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20150276766A1 (enExample) |
| EP (2) | EP2912462B1 (enExample) |
| JP (3) | JP6401171B2 (enExample) |
| CN (2) | CN104968801B (enExample) |
| AU (3) | AU2013334659B2 (enExample) |
| CA (1) | CA2889209C (enExample) |
| ES (2) | ES3031001T3 (enExample) |
| IL (3) | IL267663B (enExample) |
| SA (1) | SA515360337B1 (enExample) |
| WO (1) | WO2014066486A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
| BRPI0618947B1 (pt) | 2005-11-23 | 2022-07-19 | Acceleron Pharma Inc | Polipeptídeo actriia que se liga à ativina, polinucleotídeo isolado, polinucleotídeo recombinante, métodopara preparar um polipeptídeo actriia que se liga à ativina, preparação farmacêutica e uso de uma proteína de fusão actriia-fc para promover o crescimento ósseo e inibir a ressorção óssea |
| US8895016B2 (en) | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
| TWI584815B (zh) | 2007-02-01 | 2017-06-01 | 艾瑟勒朗法瑪公司 | 活化素-ＡｃｔＲＩＩａ拮抗劑及其治療或預防乳癌之用途 |
| TW201627320A (zh) | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| MX2009008510A (es) | 2007-02-09 | 2010-01-15 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para promover el crecimiento de huesos en pacientes con cancer. |
| CA2699936A1 (en) | 2007-09-18 | 2009-03-26 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| CN107267520A (zh) | 2009-06-12 | 2017-10-20 | 阿塞勒隆制药公司 | 截短的actriib‑fc融合蛋白 |
| ES2658292T3 (es) | 2009-11-17 | 2018-03-09 | Acceleron Pharma, Inc. | Proteínas ActRIIB y variantes y usos de las mismas con respecto a la inducción de la utrofina para el tratamiento de la distrofia muscular |
| CA2817008A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
| RU2678117C2 (ru) | 2012-11-02 | 2019-01-23 | Селджин Корпорейшн | Антагонисты активина-actrii и их применение для лечения нарушений костной ткани и других нарушений |
| EP3131931B1 (en) * | 2014-04-18 | 2020-10-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating sickle-cell disease |
| CN114699529A (zh) | 2014-06-13 | 2022-07-05 | 阿塞勒隆制药公司 | 用于治疗溃疡的方法和组合物 |
| MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
| RU2708170C2 (ru) * | 2014-11-24 | 2019-12-04 | Сомалоджик, Инк. | Соединения нуклеиновой кислоты для связывания ростового фактора дифференцировки 11 |
| EP3227675B1 (en) * | 2014-12-03 | 2023-03-15 | Celgene Corporation | Activin-actrii antagonists and uses for treating myelodysplastic syndrome |
| CA2983440C (en) | 2015-04-22 | 2024-03-12 | Alivegen Usa Inc. | Novel hybrid actriib ligand trap proteins for treating muscle wasting diseases |
| TWI814187B (zh) * | 2015-05-13 | 2023-09-01 | 美商西建公司 | 使用ACTRII配位體捕捉以治療β-地中海型貧血 |
| EP3298034A4 (en) * | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
| EP3370754B1 (en) | 2015-11-04 | 2026-04-29 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
| CN105738614B (zh) * | 2016-02-23 | 2017-12-05 | 山东大学 | 一种应用流式细胞仪分析评价小鼠骨髓红细胞生成功能的方法 |
| LT3490582T (lt) | 2016-07-27 | 2024-07-25 | Acceleron Pharma Inc. | Kompozicijos, skirtos naudoti gydant mielofibrozę |
| JOP20190085A1 (ar) | 2016-10-20 | 2019-04-17 | Biogen Ma Inc | طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة |
| CA3177632A1 (en) | 2020-05-15 | 2021-11-18 | Melih ACAR | Methods and compositions for treating anemia using actriib ligand traps and mtor inhibitors |
| US12186370B1 (en) | 2020-11-05 | 2025-01-07 | Celgene Corporation | ACTRIIB ligand trap compositions and uses thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS63502716A (ja) | 1986-03-07 | 1988-10-13 | マサチューセッツ・インステチュート・オブ・テクノロジー | 糖タンパク安定性の強化方法 |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
| US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
| DE69534468T2 (de) * | 1994-07-08 | 2006-07-13 | The Johns Hopkins University School Of Medicine | Wachstums-differenzierungsfaktor-11 |
| US6891082B2 (en) * | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
| AU8921698A (en) | 1997-08-29 | 1999-03-16 | Human Genome Sciences, Inc. | Follistatin-3 |
| CA2418835A1 (en) | 2000-10-16 | 2002-04-25 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
| TWI329129B (en) * | 2001-02-08 | 2010-08-21 | Wyeth Corp | Modified and stabilized gdf propeptides and uses thereof |
| JP4369662B2 (ja) | 2001-04-26 | 2009-11-25 | アビディア インコーポレイテッド | 単量体ドメインのコンビナトリアルライブラリー |
| PL374966A1 (en) * | 2002-02-21 | 2005-11-14 | Wyeth | Follistatin domain containing proteins |
| WO2005025601A1 (en) | 2003-09-15 | 2005-03-24 | Monash University | Follistatin isoforms and uses thereof |
| JP2008507288A (ja) | 2004-07-23 | 2008-03-13 | アクセルロン ファーマ インコーポレーテッド | ＡｃｔＲＩＩ受容体ポリペプチド、方法、および組成物 |
| CA2587424A1 (en) | 2004-11-16 | 2006-05-26 | Avidia Research Institute | Protein scaffolds and uses thereof |
| US8067562B2 (en) * | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
| WO2008030367A2 (en) | 2006-09-01 | 2008-03-13 | The General Hospital Corporation | Selective myostatin inhibitors |
| CA2672758C (en) * | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
| TW201627320A (zh) * | 2007-02-02 | 2016-08-01 | 艾瑟勒朗法瑪公司 | 衍生自ＡｃｔＲＩＩＢ的變體與其用途 |
| EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
| US8216997B2 (en) * | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
| DK3750552T5 (da) | 2008-08-14 | 2024-08-26 | Acceleron Pharma Inc | Gdf-fælder |
| ES2655877T3 (es) * | 2009-04-27 | 2018-02-22 | Novartis Ag | Composiciones y métodos para aumentar el crecimiento muscular |
| KR102170682B1 (ko) | 2009-08-13 | 2020-10-28 | 악셀레론 파마 인코포레이티드 | 적혈구 수준을 증가시키기 위한 ｇｄｆ 트랩과 에리트로포이에틴 수용체 활성인자의 병용 |
| CA2817008A1 (en) * | 2010-11-08 | 2012-05-18 | Acceleron Pharma Inc. | Actriia binding agents and uses thereof |
-
2013
- 2013-10-23 CA CA2889209A patent/CA2889209C/en active Active
- 2013-10-23 US US14/438,120 patent/US20150276766A1/en not_active Abandoned
- 2013-10-23 IL IL267663A patent/IL267663B/en unknown
- 2013-10-23 EP EP13848471.2A patent/EP2912462B1/en active Active
- 2013-10-23 ES ES19184182T patent/ES3031001T3/es active Active
- 2013-10-23 EP EP19184182.4A patent/EP3608419B1/en active Active
- 2013-10-23 AU AU2013334659A patent/AU2013334659B2/en active Active
- 2013-10-23 JP JP2015539750A patent/JP6401171B2/ja active Active
- 2013-10-23 ES ES13848471T patent/ES2753811T3/es active Active
- 2013-10-23 WO PCT/US2013/066350 patent/WO2014066486A2/en not_active Ceased
- 2013-10-23 CN CN201380067792.8A patent/CN104968801B/zh active Active
- 2013-10-23 CN CN202110622231.6A patent/CN113604550A/zh active Pending
- 2013-10-23 IL IL290653A patent/IL290653B2/en unknown
-
2015
- 2015-04-21 IL IL238414A patent/IL238414B/en active IP Right Grant
- 2015-04-23 SA SA515360337A patent/SA515360337B1/ar unknown
-
2018
- 2018-03-09 US US15/916,634 patent/US20190049469A1/en not_active Abandoned
- 2018-07-11 JP JP2018131226A patent/JP2018184428A/ja active Pending
-
2019
- 2019-06-12 AU AU2019204098A patent/AU2019204098B2/en active Active
-
2020
- 2020-06-24 JP JP2020108569A patent/JP7146850B2/ja active Active
-
2021
- 2021-09-21 AU AU2021236465A patent/AU2021236465B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020183389A5 (enExample) | ||
| Guida et al. | Strategies to prevent or remediate cancer and treatment-related aging | |
| JP2018184428A5 (enExample) | ||
| Giovannoni et al. | Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial | |
| Wendler et al. | Immune modulation to enhance bone healing—a new concept to induce bone using prostacyclin to locally modulate immunity | |
| Wilson et al. | Cathepsin G-mediated enhanced TGF-β signaling promotes angiogenesis via upregulation of VEGF and MCP-1 | |
| Amer et al. | Oral paricalcitol reduces the prevalence of posttransplant hyperparathyroidism: results of an open label randomized trial | |
| Tamari et al. | Endothelial Progenitor Cells inhibit jaw osteonecrosis in a rat model: A major adverse effect of bisphosphonate therapy | |
| Rodimova et al. | Effect of hepatic pathology on liver regeneration: the main metabolic mechanisms causing impaired hepatic regeneration | |
| JP2016503398A5 (enExample) | ||
| FI3227675T3 (fi) | Aktiviini-actrii-antagonisteja ja niiden käyttöjä myelodysplastisen oireyhtymän hoitamiseksi | |
| Takeuchi et al. | Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study) | |
| Watanabe et al. | Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: a phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan | |
| JP2015523553A5 (enExample) | ||
| CN116782934A (zh) | 抗半乳糖凝集素9抗体及其在治疗眼部黑素瘤中的用途 | |
| Shah et al. | Biomolecular components of blood and their role in health and diseases | |
| Locatelli et al. | Defining curative endpoints for sickle cell disease in the era of gene therapy and gene editing | |
| Gilbertson et al. | Hemoglobin level variability: anemia management among variability groups | |
| Rölfing | The effect of erythropoietin on bone | |
| Ma et al. | Skeletal muscle dysfunction induced by cancer immunotherapy: mechanistics insights and surgical implications | |
| El Hoss et al. | Erythropoiesis in health and disease: Distinguishing defective and ineffective erythropoiesis | |
| Fallet et al. | Current immunosuppressive and antifibrotic therapies of systemic sclerosis and emerging therapeutic strategies | |
| Schmid et al. | New strategies for managing anemia of chronic kidney disease | |
| CN120322235A (zh) | 通过施用利扎鲁替尼治疗患有认知损害的受试者中的免疫性血小板减少症的方法 | |
| Kodali et al. | TTP-like syndrome associated with hemoglobin SC disease treated successfully with plasma and red cell exchange |